Roselyn v. Fleishman

882 S.W.2d 219, 1994 Mo. App. LEXIS 1036, 1994 WL 269575
CourtMissouri Court of Appeals
DecidedJune 21, 1994
DocketWD 48233
StatusPublished
Cited by18 cases

This text of 882 S.W.2d 219 (Roselyn v. Fleishman) is published on Counsel Stack Legal Research, covering Missouri Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Roselyn v. Fleishman, 882 S.W.2d 219, 1994 Mo. App. LEXIS 1036, 1994 WL 269575 (Mo. Ct. App. 1994).

Opinion

LOWENSTEIN, Presiding Judge.

Roselyn Green and her husband, Dorvin Green, appeal from an order of the trial court granting a directed verdict in a medical negligence case, on behalf of defendants Sheldon Fleishman, D.P.M., Upjohn Healthcare Services, Inc., and Caremark, Inc. The Greens contend the trial court first erred by striking the testimony of their only expert witness on the issue of causation and then granting a directed verdict.

The core issue on appeal is the court’s striking of plaintiffs’ expert’s trial testimony, which opined medical negligence by the defendants, which came without explanation over one year following the expert’s deposition where, when asked the same question, he reached no opinion as to negligent treatment or care.

In April, 1988, Roselyn Green was hospitalized for a foot infection at the Medical Center of Independence, where her treatment was managed by Steven Gialde, D.O. and respondent, Dr. Fleishman, a podiatrist, who acted as a consultant. As part of her treatment, Mrs. Green was given periodic dosages of gentamicin, an antibiotic, the use of which may result in possible toxic side effects. During her hospitalization, Mrs. Green was monitored to ensure that the levels of the drug in her blood were safe.

After eleven days of hospitalization, Mrs. Green continued the intravenous gentamicin therapy at home under the supervision of home health care providers, Upjohn Healthcare Services, Inc. and Caremark Inc. The defendant, Caremark, acted as the pharmacy and compounded the medication; the defendant, Upjohn’s role as home healthcare agency, was to visit the home 3 days per week and, as relevant here, help with out-patient administration of medication. Despite the fact that Mrs. Green was receiving gentami-cin at the same dosage and frequency as she received at the hospital, Gialde did not order out-patient monitoring to ensure that the quantity of the drug in her system did not exceed safe levels. As stated in the previous paragraph, gentamicin is a powerful drug which may accumulate in the blood with toxic effects, which then outweigh its therapeutic effect.

On May 10, 1988, after seventeen days of unmonitored home gentamicin therapy, Mrs. Green suffered a spell of dizziness and a loss of balance. These problems persisted and the Greens filed this petition alleging medical negligence for Mrs. Green’s permanent dizziness and disequilibrium, loss of consortium, and sought damages from Dr. Fleishman, Dr. Gialde, Upjohn Healthcare Services, Inc., and Caremark, Inc. The basic theory of the lawsuit was Mrs. Green should have been monitored for toxic side effects of gentamicin following her hospitalization and that all the defendants owed her a duty to monitor. Dr. Gialde subsequently settled with the Greens for $425,000.00.

Dr. Larry Rumans, the Greens’ medical expert on the issue of causation, was deposed prior to trial. During his deposition, Dr. Rumans was asked numerous questions about the dosages of gentamicin and the relationship of the drug to Mrs. Green’s condition:

Q. [DEFENSE COUNSEL]: And, in fact, sir, are you able to point to anything in the medical records that suggests that Mrs. Green’s blood levels of this medication exceeded the maximum therapeutic level?
A. [DR. RUMANS]: Not during her hospitalization.
Q. Are you able to point to anything which would suggest that if those blood *221 levels were on the low side, given the certain dosage of Gentamicin during hospitalization, that they would have been expected to exceed therapeutic levels during out-patient therapy?
A. Well, the whole point is, Mr. Emerson, that we have no data as to what occurred as an outpatient, and so it is all speculation.
Q. That really is my point, I guess. You are not rendering an opinion, are you, that Mrs. Green’s imbalance problems resulted from concentrations of Gentamicin in her blood that exceeded maximum therapeutic levels, are you?
A. Well, you see that is just it. We don’t know.
Q. Well, that is my question, you are not suggesting that, are you?
A. I am not necessarily suggesting it, but I am saying that it could have happened.
Q. Okay. My question is whether or not you hold an opinion within a reasonable degree of medical certainty as to whether or not Mrs. Green’s blood levels of Gen-tamicin exceeded the maximum therapeutic or the allowable therapeutic doses while she was an outpatient?
A. I have no opinion.
Q. Okay. My next question is whether you hold an opinion within a reasonable degree of medical certainty as to whether the ototoxic effects, which you believe Mrs. Green suffered, resulted from excessive blood levels of Gentamicin?
A. I believe that the ototoxicity that was experienced occurred as a result of excessive aminoglycosides, accumulation and concentration at the site where toxicity occurred, and that may have been related to excessive blood levels.
Q. Do you have any objective evidence whatsoever to support your speculation that there may have been excessive levels of Gentamicin?
A. Well, again, I have to go back. There is no data, Mr. Emerson.
Q. Okay.
A. So that my speculation it occurred is just as good as anyone’s speculation that it didn’t occur.
Q. And you wouldn’t hold out that speculation as being an opinion with a reasonable degree of medical certainty, would you?
A. No, sir. (Emphasis added).

At trial, approximately fourteen months later, Dr. Rumans was asked whether Mrs. Green had toxic levels of gentamicin in her system:

Q. Given the data that you have, all the data with regard to Roselyn Green’s tolerance of the drug in the hospital setting and the fact that no laboratory monitoring was done during the 17-day period and your testimony that Gentamicin levels increase in the body with time and with additional dosages, does that data provide you with an inferential basis which allows you to determine, within a reasonable degree of medical certainty, as to whether the levels of Gentamicin went into the toxic range during that 17-day period?
A. I believe that it’s likely that the levels did increase to a toxic range.

After the Greens had presented their evidence on the issue of liability, the defendants moved to strike Dr. Rumans’ trial testimony on the grounds that it differed from his deposition testimony and constituted an unfair surprise. The motion was granted by the trial court, which ordered that “the testimony of Larry Rumans, M.D. relating to whether the plaintiffs blood levels of gen-tamicin exceeded the maximum therapeutic or allowable levels be stricken.” All the defendants then moved for a directed verdict which was granted.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

White v. City of Ladue
422 S.W.3d 439 (Missouri Court of Appeals, 2013)
Beaty v. St. Luke's Hospital of Kansas City
298 S.W.3d 554 (Missouri Court of Appeals, 2009)
Bradford v. BJC CORPORATE HEALTH SERVICES
200 S.W.3d 173 (Missouri Court of Appeals, 2006)
Eagan v. Duello
173 S.W.3d 341 (Missouri Court of Appeals, 2005)
Zimmer v. Fisher
171 S.W.3d 76 (Missouri Court of Appeals, 2005)
Redel v. Capital Region Medical Center
165 S.W.3d 168 (Missouri Court of Appeals, 2005)
Scott v. LeClercq
136 S.W.3d 183 (Missouri Court of Appeals, 2004)
Whitted v. Healthline Management, Inc.
90 S.W.3d 470 (Missouri Court of Appeals, 2002)
Bernstein v. Martin
Maine Superior, 2000
Sanders v. Hartville Milling Co.
14 S.W.3d 188 (Missouri Court of Appeals, 2000)
Zerjav v. Schneider
998 S.W.2d 44 (Missouri Court of Appeals, 1999)
Bray v. Bi-State Development Corp.
949 S.W.2d 93 (Missouri Court of Appeals, 1997)
Luster v. Gastineau
916 S.W.2d 842 (Missouri Court of Appeals, 1996)
City of Joplin v. Flinn
914 S.W.2d 398 (Missouri Court of Appeals, 1996)
Blake v. Irwin
913 S.W.2d 923 (Missouri Court of Appeals, 1996)
Cooper v. Ketcherside
907 S.W.2d 259 (Missouri Court of Appeals, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
882 S.W.2d 219, 1994 Mo. App. LEXIS 1036, 1994 WL 269575, Counsel Stack Legal Research, https://law.counselstack.com/opinion/roselyn-v-fleishman-moctapp-1994.